Literature DB >> 21966471

Antibodies to henipavirus or henipa-like viruses in domestic pigs in Ghana, West Africa.

David T S Hayman1, Lin-Fa Wang, Jennifer Barr, Kate S Baker, Richard Suu-Ire, Christopher C Broder, Andrew A Cunningham, James L N Wood.   

Abstract

Henipaviruses, Hendra virus (HeV) and Nipah virus (NiV), have Pteropid bats as their known natural reservoirs. Antibodies against henipaviruses have been found in Eidolon helvum, an old world fruit bat species, and henipavirus-like nucleic acid has been detected in faecal samples from E. helvum in Ghana. The initial outbreak of NiV in Malaysia led to over 265 human encephalitis cases, including 105 deaths, with infected pigs acting as amplifier hosts for NiV during the outbreak. We detected non-neutralizing antibodies against viruses of the genus Henipavirus in approximately 5% of pig sera (N = 97) tested in Ghana, but not in a small sample of other domestic species sampled under a E. helvum roost. Although we did not detect neutralizing antibody, our results suggest prior exposure of the Ghana pig population to henipavirus(es). Because a wide diversity of henipavirus-like nucleic acid sequences have been found in Ghanaian E. helvum, we hypothesise that these pigs might have been infected by henipavirus(es) sufficiently divergent enough from HeVor NiV to produce cross-reactive, but not cross-neutralizing antibodies to HeV or NiV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21966471      PMCID: PMC3178620          DOI: 10.1371/journal.pone.0025256

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

The genus Henipavirus in the family Paramyxoviridae is comprised of Hendra (HeV) and Nipah (NiV) viruses. These viruses use bats of the family Pteropodidae as their natural reservoir hosts [1], [2]. Henipaviruses have a remarkably wide susceptible host range and represent some of the most pathogenic viruses known, each capable of causing an often fatal encephalitis or severe respiratory disease and both are classified as biosafety level 4 pathogens. Outbreaks of NiV in Malaysia, India and Bangladesh have had case fatality rates ranging from 40–90% [3], [4], [5]. The Malaysian NiV epidemic led to over 265 human encephalitis cases, with 105 deaths [4]. To date, two domestic species are known to have served as amplifying hosts for henipaviruses prior to transmission to humans; horses for HeV and pigs for NiV. Infected pigs acted as amplifier hosts for NiV during the Malaysian NiV outbreak, and over one million pigs were culled to contain the epidemic [6], [7]. Furthermore, both cats and dogs have been found to be positive (NiV-cats) or seropositive (NiV and HeV-dogs) [7], [8]. We previously reported serological evidence for henipavirus infection in Eidolon helvum bats in Ghana, West Africa [9]. Eidolon helvum roosts in large colonies, reaching several million in number, and has a wide distribution across the African continent. Those findings thus extended the range of henipaviruses from Asia and Australasia to Africa. A subsequent study found henipavirus-like nucleic acid in faecal samples from E. helvum in Ghana [10]. We therefore hypothesised that domestic animal species that have previously acted as amplifier hosts elsewhere may have been exposed to henipavirus infection in Africa. To test this hypothesis, we screened a selection of domestic animal sera from animals within the grounds of the 37 Military Hospital, Accra, Ghana, where a large E. helvum colony (up to 1 million individual animals) resides for approximately 6 months during each dry season.

Methods

Ethical approval for this project (WLE/0467) was received from the Zoological Society of London Ethics Committee and locally from the Ghanaian Veterinary Services Directorate. Serum samples were collected in June 2007 from 2 cats, 2 dogs, 10 sheep and 15 goats. In addition, 97 pig samples were available from 2 villages, collected as part of a Trypanosoma study undertaken at the Veterinary Services Laboratory, Ghana. Both villages are in the Suhum/Kraboa/Coalta district, Eastern Region, about 70 km north of Accra. Sample numbers P1–48 and P50 were from 25 households in Kwesikonfo (N 6°33; W 0° 33) and P52–64 and P66–100 from 11 households in Zorh (N 5°59 W 0°21). The bat-pig contact history was unknown. However, villages contain fruit trees and the pigs were housed in open pens (1–10/pen), with some running free during the day, and bats of numerous species have been caught by the authors foraging in other villages in the region [9], [11]. All sera were tested for antibodies binding to both a HeV and NiV recombinant soluble G glycoprotein (sG) using a Luminex® multiplexed binding assay, as described previously [9], [12]. Viral envelope glycoproteins have previously been demonstrated to be the primary protein for paramyxovirus attachment and virus entry, and also the principle viral antigens that inducer neutralizing antibodies in hosts [13]. The recombinant sG proteins used in the Luminex assay were generated using a mammalian expression system in a soluble and oligomeric form by removing the transmembrane domain, and purified sG was coupled to microspheres as described previously [12]. For all test samples sGNiV and sGHeV-coupled microsphere subsets were pre-mixed and incubated with sera, followed by incubation with biotinylated Protein A/G and streptavidin–phycoerythrin. Antibodies bound to the sGNiV or sGHeV coated beads, which are spectrally distinct, are quantified by the fluorescence emitted by phycoerythrin. This is read as the median fluorescence intensity (M.F.I.). Gamma-irradiated positive pig and cat sera controls from naturally or experimentally infected animals, and negative controls from each species were used. Putative positive sera, with M.F.I. titres 3-fold above the negative sera M.F.I., were then tested using a Luminex ephrin-B2 receptor blocking (inhibition) assay and by virus neutralization tests (VNTs) [12]. Field samples of HeV infected horse and NiV infected pig sera has previously been demonstrated to block ephrin-B2-G glycoprotein interactions in a dose dependent fashion [12]. For the VNTs, sera were tested against both NiV and HeV at a 1∶10 dilution. Finally, 7 pig sera with high Luminex binding titres, and 1 with a low Luminex binding titre (P17) were tested by western blot (WB). The WB was performed using purified recombinant Nipah virus nucleocapsid (N) protein produced as previously described [14]. Briefly, 50µg of purified NiV N protein was separated using SDS-PAGE on a 12% gel using a wide preparative comb, followed by electroblotting onto a nitrocellulose membrane and blocked overnight in blocking buffer (5% w/v Skim Milk Powder in TBS buffer). The nitrocellulose membrane was cut into strips and incubated for 1h with individual sera (diluted 1∶50 in blocking buffer). Negative controls were a negative pig serum and blocking buffer alone, with NiV-neutralizing human and pig sera as positive controls. Following washing, the strips were incubated for 1h with a protein A/G alkaline phosphatase conjugate (Thermo-Fisher Scientific Inc., USA) at 1∶2000 in blocking buffer. Following washing, alkaline phosphatase substrates were added and allowed to develop for 15 minutes. The marker used was Benchmark prestained protein ladder (Invitrogen, UK).

Results

One goat (G) and one sheep (S) sample each had M.F.I. titres well above 3 times background for NiV and HeV respectively. G15′s titre was 584 M.F.I. against NiV (>3 times mean negative sera M.F.I. of 62), but only produced a titre of 71.5 M.F.I. against HeV (negative sera M.F.I. 62). Sheep S7′s M.F.I. titre was 521 against HeV (>3 times mean negative sera M.F.I. of 81), but only 86 M.F.I. against NiV (negative sera M.F.I. 66) (see Figure 1). Neither these, nor 4 further goat and 1 further sheep sera tested, were positive using the inhibition assay. Pig sera were tested in 2-sample pools (N = 74 samples) or individually (N = 23) (see Figure 2). Inhibition was then tested on individual samples for those with high binding readings (see Figure 3). Of those tested, 5/18 (5.2% of the total pig sera) had high levels (>20%) of inhibition. Sample P29 gave 74% inhibition. This is high and comparable to the NiV-positive pig control inhibition of 90%. P29 was one of a pool of sera tested with another sample by Luminex sG binding, and therefore diluted 1∶2 for the original test. This pool had a titre of 2638 M.F.I., compared to a NiV positive pig titre of 6043 M.F.I.
Figure 1

The M.F.I. of anti-NiV (Red) and HeV (Blue) antibodies from 2 cats (C), 2 dogs (D), 10 sheep (S) and 15 goats (G) from Ghana with NiV positive cat and negative (all species) control.

Figure 2

The median fluorescent intensities (M.F.I.) of 97 pig (P) sera from Ghana tested in pools of 2 or singly for antibodies against Nipah (NiV-Red) and Hendra (HeV-Blue) virus soluble glycoprotein (sG) attached to microspheres on the Luminex platform.

Positive and negative serum controls are shown.

Figure 3

Percentage inhibition of NiV and HeV sG-Ephrin-B2 receptor by Luminex binding assay positive pig (P) sera, with NiV positive and negative controls.

The median fluorescent intensities (M.F.I.) of 97 pig (P) sera from Ghana tested in pools of 2 or singly for antibodies against Nipah (NiV-Red) and Hendra (HeV-Blue) virus soluble glycoprotein (sG) attached to microspheres on the Luminex platform.

Positive and negative serum controls are shown. All sera tested for inhibition (5 goat, 2 sheep and 18 pig) were tested by VNTs, but no sera tested positive using VNTs. However, one (P92) of the seven binding-antibody positive pig sera tested positive by WB against the N protein (Figure 4), thus confirming non-neutralizing antibody against another NiV protein. No further sample was available for P29 for testing by WB. The additional WB staining seen in all samples except P92 is thought to be non-specific background staining.

The results of western blot analysis against Nipah virus nucleocapsid protein of seven Ghanaian pig sera (designated P) with high Luminex binding assay titres and one (P17) with a low binding assay titre against soluble henipavirus glycoproteins.

The marker is BenchMark Pre-stained Protein Ladder (Invitrogen); the positive sera NiV virus neutralization test positive pig and human field sera; the negative control sera negative pig and skimmed milk powder (SMP).

Discussion

Our results suggest evidence of prior exposure of the Ghana pig population to henipavirus(es). The wide diversity of henipavirus-like nucleic acid sequences that have been found in Ghanaian bats [10] means that it is possible that these pigs have been infected by henipavirus(es) divergent enough from HeV or NiV to produce glycoprotein binding antibodies, but not HeV or NiV neutralizing antibodies [15]. Luminex binding assay has been demonstrated to give preferentially higher M.F.I. for the virus that induced antibody from field sera of NiV infected pigs from the 1998–1999 NiV outbreak in Malaysia and Singapore, and HeV infected horses from the 1994 HeV outbreak [12]. While it is possible that the positive results found against both virus sG in this study are due to broad high background binding, the lack of this finding in Malaysian pig sera from the 1998–1999 outbreak and the relatively high inhibition of ephrin-B2-G glycoprotein interactions (Figure 3) are suggestive of previous exposure to henipaviruses. In addition to this, binding was confirmed on another platform, WB, and against another protein (N) by a single serum sample. This sample (P92) had demonstrated 40% sG-Ephrin B2 receptor inhibition and had a Luminex binding M.F.I. titre 27-fold higher than the negative pig control serum. Although the non-specific staining by other positive sera is undesirable, pig sera have been shown previously to be reactive for non-specific stains, particularly to E. coli proteins. However, given binding antibody had previously been demonstrated against sG NiV proteins in this sample of pig sera, we believe this adds further evidence of infection by a NiV or Nipah-related virus in these populations. The mechanisms of virus neutralization are complex and could involve more antigenic sites than those required for simple receptor binding or inhibition. The failure of finding VNT positive sera therefore may be due to the divergent nature of the viruses inducing antibody. As has been shown in studies on bats in Ghana, only a relatively small proportion of those seropositive by Luminex assay were VNT positive, and subsequent studies by others have shown related but divergent henipavirus sequences from the same bat species. Furthermore, previous studies have shown the NiV antibody positive pig sera produced lower titres than human (NiV, HeV), bat (HeV) and horse (HeV) positive sera using all three (binding, receptor inhibition and neutralization) assays [12]. Laboratory studies suggest viral replication in bats is limited [16], [17] and bat-to-human transmission outside of Bangladesh is yet to be reported. Therefore, evidence of infection in potential amplifying hosts in Ghana is an important finding, whether due to multiple introductions or a single introduction of infection with subsequent pig-to-pig transmission. It is unknown which is the cause of the Ghanaian pig serological results here, however, both are important events that may lead to henipavirus emergence by altering infection dynamics within the populations on subsequent re-introduction [18]. Further sera from these animals are unavailable for additional testing; however, future sampling should be age-specific in order to make inferences relating to infection dynamics in the pig populations. Finally, E. helvum frequently roosts in urban areas, is a source of bushmeat [9], [11] and is known to forage in semi-urban areas [19], and we are therefore currently increasing the study size and extending it to include humans and animals in high risk groups of exposure to bats in order to determine the likelihood of exposure to potentially-fatal zoonotic viruses.
  16 in total

1.  Isolation of Nipah virus from Malaysian Island flying-foxes.

Authors:  Kaw Bing Chua; Chong Lek Koh; Poh Sim Hooi; Kong Fatt Wee; Jenn Hui Khong; Beng Hooi Chua; Yee Peng Chan; Mou Eng Lim; Sai Kit Lam
Journal:  Microbes Infect       Date:  2002-02       Impact factor: 2.700

2.  Nipah virus: a recently emergent deadly paramyxovirus.

Authors:  K B Chua; W J Bellini; P A Rota; B H Harcourt; A Tamin; S K Lam; T G Ksiazek; P E Rollin; S R Zaki; W Shieh; C S Goldsmith; D J Gubler; J T Roehrig; B Eaton; A R Gould; J Olson; H Field; P Daniels; A E Ling; C J Peters; L J Anderson; B W Mahy
Journal:  Science       Date:  2000-05-26       Impact factor: 47.728

3.  A comparative indirect ELISA for the detection of henipavirus antibodies based on a recombinant nucleocapsid protein expressed in Escherichia coli.

Authors:  Ji-Ming Chen; Meng Yu; Chris Morrissy; Yong-Gang Zhao; Greer Meehan; Ying-Xue Sun; Qing-Hua Wang; Wei Zhang; Lin-Fa Wang; Zhi-Liang Wang
Journal:  J Virol Methods       Date:  2006-09       Impact factor: 2.014

4.  Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia.

Authors:  K B Chua; K J Goh; K T Wong; A Kamarulzaman; P S Tan; T G Ksiazek; S R Zaki; G Paul; S K Lam; C T Tan
Journal:  Lancet       Date:  1999-10-09       Impact factor: 79.321

5.  Experimental Nipah virus infection in pigs and cats.

Authors:  D J Middleton; H A Westbury; C J Morrissy; B M van der Heide; G M Russell; M A Braun; A D Hyatt
Journal:  J Comp Pathol       Date:  2002 Feb-Apr       Impact factor: 1.311

6.  Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis.

Authors:  Juliet R C Pulliam; Jonathan H Epstein; Jonathan Dushoff; Sohayati A Rahman; Michel Bunning; Aziz A Jamaluddin; Alex D Hyatt; Hume E Field; Andrew P Dobson; Peter Daszak
Journal:  J R Soc Interface       Date:  2011-06-01       Impact factor: 4.118

7.  Antibodies against Lagos bat virus in megachiroptera from West Africa.

Authors:  David T S Hayman; Anthony R Fooks; Daniel Horton; Richard Suu-Ire; Andrew C Breed; Andrew A Cunningham; James L N Wood
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

8.  Nipah virus-associated encephalitis outbreak, Siliguri, India.

Authors:  Mandeep S Chadha; James A Comer; Luis Lowe; Paul A Rota; Pierre E Rollin; William J Bellini; Thomas G Ksiazek; Akhilesh Mishra
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

9.  Evidence of henipavirus infection in West African fruit bats.

Authors:  David T S Hayman; Richard Suu-Ire; Andrew C Breed; Jennifer A McEachern; Linfa Wang; James L N Wood; Andrew A Cunningham
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

10.  Henipavirus RNA in African bats.

Authors:  Jan Felix Drexler; Victor Max Corman; Florian Gloza-Rausch; Antje Seebens; Augustina Annan; Anne Ipsen; Thomas Kruppa; Marcel A Müller; Elisabeth K V Kalko; Yaw Adu-Sarkodie; Samuel Oppong; Christian Drosten
Journal:  PLoS One       Date:  2009-07-28       Impact factor: 3.240

View more
  35 in total

Review 1.  Nipah virus matrix protein: expert hacker of cellular machines.

Authors:  Ruth E Watkinson; Benhur Lee
Journal:  FEBS Lett       Date:  2016-07-12       Impact factor: 4.124

2.  Attachment protein G of an African bat henipavirus is differentially restricted in chiropteran and nonchiropteran cells.

Authors:  Nadine Krüger; Markus Hoffmann; Jan Felix Drexler; Marcel Alexander Müller; Victor Max Corman; Christian Drosten; Georg Herrler
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

Review 3.  Changing resource landscapes and spillover of henipaviruses.

Authors:  Maureen K Kessler; Daniel J Becker; Alison J Peel; Nathan V Justice; Tamika Lunn; Daniel E Crowley; Devin N Jones; Peggy Eby; Cecilia A Sánchez; Raina K Plowright
Journal:  Ann N Y Acad Sci       Date:  2018-08-23       Impact factor: 5.691

4.  Hendra virus and Nipah virus animal vaccines.

Authors:  Christopher C Broder; Dawn L Weir; Peter A Reid
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

Review 5.  Transmission of henipaviruses.

Authors:  Sarah Weatherman; Heinz Feldmann; Emmie de Wit
Journal:  Curr Opin Virol       Date:  2017-10-14       Impact factor: 7.090

Review 6.  Immunization strategies against henipaviruses.

Authors:  Christopher C Broder; Thomas W Geisbert; Kai Xu; Dimitar B Nikolov; Lin-Fa Wang; Deborah Middleton; Jackie Pallister; Katharine N Bossart
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 7.  Henipavirus receptor usage and tropism.

Authors:  Olivier Pernet; Yao E Wang; Benhur Lee
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 8.  Zoonotic Potential of Emerging Paramyxoviruses: Knowns and Unknowns.

Authors:  Patricia A Thibault; Ruth E Watkinson; Andres Moreira-Soto; Jan F Drexler; Benhur Lee
Journal:  Adv Virus Res       Date:  2017-02-02       Impact factor: 9.937

9.  Surface glycoproteins of an African henipavirus induce syncytium formation in a cell line derived from an African fruit bat, Hypsignathus monstrosus.

Authors:  Nadine Krüger; Markus Hoffmann; Michael Weis; Jan Felix Drexler; Marcel Alexander Müller; Christine Winter; Victor Max Corman; Tim Gützkow; Christian Drosten; Andrea Maisner; Georg Herrler
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

10.  Nipah Virus Matrix Protein Influences Fusogenicity and Is Essential for Particle Infectivity and Stability.

Authors:  Erik Dietzel; Larissa Kolesnikova; Bevan Sawatsky; Anja Heiner; Michael Weis; Gary P Kobinger; Stephan Becker; Veronika von Messling; Andrea Maisner
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.